Search results for:
levoFLOXacin
levoFLOXacin
| Drug Name |
Form |
Strength |
Non-Formulary |
Restricted |
TX Sub |
Notes |
| Levaquin |
SOLUTION, INTRAVENOUS |
250 mg/50 mL; 500 mg/100 mL; 750 mg/150 mL |
|
|
|
|
| Levaquin |
SOLUTION, ORAL |
250 mg/10 mL |
|
|
|
|
| Levaquin |
TABLET, ORAL |
250 mg; 500 mg |
|
|
|
|
Last updated: Jun. 4, 2025
(Brand)
• Indications
Comments
(Levaquin©)
• Healthcare-associated Pneumonia (HAP) (7-14 days)
• Community-acquired Pneumonia (CAP) (5 days)
• Cellulitis
• Severe infection
CrCl 20-50: 750 mg q48h
CrCl < 20: 750 mg x1, then 500 mg q48h
HD, intermittent (3x/week): 750 mg x 1 then EITHER 500 mg q48h OR 250 mg q24h
(Levaquin©)
• Community-acquired pneumonia (7-14 days)
• Other infections
CrCl 20-50: 500 mg x1, then 250 mg q24h
CrCl < 20: 500 mg x1, then 250 mg q48h
HD, intermittent (3x/week): 500 mg x 1 then EITHER 250 mg q48h OR 125 mg q24h
(Levaquin©)
• Uncomplicated UTI
CrCl < 20: 250 mg q48h (unless uncomplicated UTI, where no adjustment is necessary)
HD, intermittent (3x/week): 250 mg q48h
(Brand)
(Levaquin)
≥5 y/o: 10 mg/kg q24h
(max: 750 mg/day)
≥5 y/o: 10 mg/kg q24h
(max: 750 mg/day)
(Brand)
(Levaquin)